| Date |
Subject |
Media |
| 2025-08-11 |
HanchorBio’s Anti-Cancer Drug HCB101 to Complete International Licensing as Early as Q4 This Year, Plans to List in Q1 Next Year
|
HanchorBio-KY, a biotech company listed on the OTC market, held an investor conference on the 22nd, during which Chairman Liu Shigao shared the latest clinical progress and future outlook for its investigational anti-cancer biologic HCB101. Liu expressed optimism that HCB101 will complete overseas market licensing between Q4 this year and Q3 next year, with a projected valuation of US$1.8 billion to $2.5 billion by year-end. The company aims for a successful listing on the stock market in Q1 of next year. |
| 2025-08-11 |
BenQ Materials Advances in Medical Business, Reports Positive Results
|
BenQ Materials, a leading polarizer manufacturer, has been actively expanding its medical business in recent years. In the last quarter, revenue from its medical segment is expected to exceed 30% of total sales, helping to optimize the product mix and improve gross margin performance. |
| 2025-08-11 |
SunWay Biotech Expands Hospital Portfolio with Distribution Rights for Four Dr. Reddy’s Drugs in Taiwan
|
Bora Health, the pharmaceutical distribution arm of SunWay Biotech, has signed a collaboration agreement with global pharmaceutical leader Dr. Reddy’s Laboratories Ltd. (Dr. Reddy’s), securing exclusive distribution rights in Taiwan for four of its products. These drugs focus on therapeutic areas including infectious diseases, central nervous system (CNS) disorders, and rare diseases, significantly enhancing Bora Health’s product lineup in the hospital channel. |
| 2025-08-11 |
APN LifeSciences Secures Strategic Investment from ADDF
|
Taiwan's biotech innovation gains global recognition. APN LifeSciences has announced a strategic investment from the Alzheimer’s Drug Discovery Foundation (ADDF). Founded by the family behind global beauty giant Estée Lauder, the ADDF’s backing will accelerate the development of APN 1607. |
| 2025-08-11 |
Migraine Diagnosis with a Single Drop of Blood Becomes Reality: Taiwan Team Led by Taipei Veterans General Hospital Develops Predictive Model with 90% Accuracy Over Five Years
|
Migraine is one of the most common neurological disorders globally, affecting an estimated 15% of the population, with over 1 billion sufferers worldwide—three times more common in women than in men. According to the Global Burden of Disease Study, migraine is the second leading cause of disability among individuals aged 15 to 49, severely impacting work, education, and quality of life. In Taiwan, approximately 2 million people experience migraine attacks each year. |
| 2025-08-11 |
GlycoNex Advances Targeted Gastric Cancer Antibody Drug GNX1021, Aiming to Launch Phase I Clinical Trial in Q2 2026
|
GlycoNex, a Taiwan-based biopharmaceutical company, announced that its antibody-drug conjugate (ADC) GNX1021, developed in collaboration with OP NanoPharma, has successfully completed pre-fill testing for clinical trial use. The results confirmed process stability and product quality in accordance with international standards. In July, GLP toxicology studies in rats and cynomolgus monkeys were also initiated, with completion expected by the fourth quarter of this year. The company plans to submit clinical trial applications to the health authorities in Taiwan and Japan in the first quarter of 2026, with the goal of launching a Phase I clinical trial in the second quarter of 2026. |
| 2025-08-11 |
Libo Pharma Completes NT$850 Million Fundraising to Accelerate Global Development of Immunotherapy Drug NM-IL-12, Targeting Q4 Emerging Stock Board Listing
|
On July 21, Libo Pharma announced the successful completion of a NT$850 million fundraising round. In addition to continued support from its parent company LIH PAO GROUP, original venture capital shareholders Beiley Biofund, Zhongjia Investment, and President International Development, this round also attracted several new investors, including Taishin Venture Capital, CDIB Healthcare II Venture Fund, Capital Venture Management, CTBC Venture Capital, and Qisda Group. Despite global economic uncertainties and tariff concerns, the company achieved this fundraising against the odds, underscoring the market’s strong confidence in Libo Pharma’s R&D capabilities and future potential. |
| 2025-08-11 |
Oneness Biotech’s New Drug “Fespixon” Receives Marketing Approval from Indonesia’s National Agency of Drug and Food Control
|
On July 18, Oneness Biotech announced that its new drug Fespixon, developed for the treatment of diabetic foot ulcers, has been granted marketing authorization by Indonesia’s National Agency of Drug and Food Control (BPOM).
The company stated that it received notification from its Indonesian consulting firm that the drug registration for Fespixon had been approved by BPOM. Following the commercial launch of this new drug in Indonesia, Oneness Biotech will pay a sales royalty to the licensor in accordance with the terms of their licensing agreement. |
| 2025-08-11 |
EirGenix Debuts on TWSE Today, Forms ADC Alliance with TTY Biopharm
|
EirGenix (Taiwan Biotech Co., Ltd.) is officially transitioning to the Taiwan Stock Exchange (TWSE) today (21st). Chairman Dr. Lee-Cheng Liu announced that in addition to the continued momentum of its CDMO business, the company has entered a strategic alliance with TTY Biopharm for the development of ADCs (antibody-drug conjugates) that combine large-molecule biologics with small-molecule drugs. Furthermore, the company’s first biosimilar for breast cancer, EG12014, has already obtained two drug licenses, which are expected to further boost its growth trajectory. |
| 2025-08-11 |
PharmaEssentia's New Drug Ropeg Applies for Regulatory Approval in Canada, Expanding Its Global PV Market Footprint
|
Last Friday (the 18th), PharmaEssentia announced a major development: the company has submitted a New Drug Submission (NDS) in Canada for its proprietary therapy BESREMi (Ropeginterferon alfa-2b, referred to as Ropeg or P1101) for the treatment of polycythemia vera (PV), marking its official entry into the Canadian market. |
